The efficacy of the BNT162b2 (COVID-19) vaccine developed by Pfizer and BioNTech declined from 96% to 84% over six months, according to an abstract released by MedRxiv ahead of publication. At the time of emergency use authorization, data beyond 2 months post-vaccination were unavailable.
Vaccine efficacy (VE) against COVID-19 was 91% through up to 6 months of follow-up, among participants and irrespective of previous SARS-CoV-2 infection. VE of 86%‒100% was seen across countries and in populations with diverse characteristics of age, sex, race/ethnicity and COVID-19 risk factors in participants without evidence of previous SARS-CoV-2 infection. VE against severe disease was 97%. In South Africa, where the SARS-CoV-2 variant of concern, B.1.351 (beta), was predominant, 100% VE was observed.
Efficacy peaked at 96.2% during the interval from 7 days to 2 months post-dose 2, and declined gradually to 83.7% from 4 months post-dose 2 to the data cut-off, an average decline of ~6% every 2 months.
In the ongoing, placebo-controlled, multinational, efficacy study, 44,165 ≥16-year-old participants and 2,264 12-15-year-old participants were randomized to receive 2 doses, 21 days apart, of the mRNA vaccines or placebo. Study endpoints reported are vaccine efficacy (VE) against laboratory-confirmed COVID-19 and safety data, both up to 6 months post-vaccination.
BNT162b2 is highly efficacious against COVID-19 and is currently authorized for emergency use or conditional approval worldwide. At the time of authorization, data beyond 2 months post-vaccination were unavailable.
BNT162b2 continued to be safe and well tolerated. Few participants had adverse events leading to study withdrawal. VE against COVID-19 was 91% through up to 6 months of follow-up, among evaluable participants and irrespective of previous SARS-CoV-2 infection.
